Difficulty: Medium
Average Score: 79%
Practice
If a patient is taking darbepoetin alfa (Aranesp), their blood counts should be monitored to determine if a dosage adjustment is needed. How soon should this be done after starting the drug?
Correct answer
A
Rationale
In the context of hematologic drugs, monitoring blood counts is crucial to ensure patient safety and efficacy of treatment. When a patient is taking darbepoetin alfa (Aranesp), which is a medication used to treat anemia by stimulating red blood cell production, regular monitoring is essential.
The correct answer is A) Six weeks if they are a cancer patient. Cancer patients often experience anemia due to their disease or treatment, and monitoring their blood counts after six weeks allows for an appropriate timeframe to assess the response to darbepoetin alfa and make any necessary dosage adjustments.
Option B) One week if they have chronic renal failure is incorrect because while patients with chronic renal failure may also benefit from darbepoetin alfa, their monitoring schedule differs from cancer patients due to the nature of their condition and response to the drug.
Option C) Two weeks if they are taking it for allogeneic transfusion is incorrect because allogeneic transfusion refers to receiving blood from a donor, and this scenario does not typically require monitoring of darbepoetin alfa usage at two-week intervals.
Option D) Each week throughout therapy is incorrect because weekly monitoring may not be necessary for all patients and can lead to unnecessary burden on healthcare resources and patient inconvenience without significant clinical benefit.
In an educational context, understanding the rationale behind monitoring protocols for hematologic drugs like darbepoetin alfa is essential for healthcare professionals to provide safe and effective care to patients. By comprehensively assessing patient needs and tailoring monitoring schedules accordingly, healthcare providers can optimize treatment outcomes and enhance patient well-being.
The correct answer is A) Six weeks if they are a cancer patient. Cancer patients often experience anemia due to their disease or treatment, and monitoring their blood counts after six weeks allows for an appropriate timeframe to assess the response to darbepoetin alfa and make any necessary dosage adjustments.
Option B) One week if they have chronic renal failure is incorrect because while patients with chronic renal failure may also benefit from darbepoetin alfa, their monitoring schedule differs from cancer patients due to the nature of their condition and response to the drug.
Option C) Two weeks if they are taking it for allogeneic transfusion is incorrect because allogeneic transfusion refers to receiving blood from a donor, and this scenario does not typically require monitoring of darbepoetin alfa usage at two-week intervals.
Option D) Each week throughout therapy is incorrect because weekly monitoring may not be necessary for all patients and can lead to unnecessary burden on healthcare resources and patient inconvenience without significant clinical benefit.
In an educational context, understanding the rationale behind monitoring protocols for hematologic drugs like darbepoetin alfa is essential for healthcare professionals to provide safe and effective care to patients. By comprehensively assessing patient needs and tailoring monitoring schedules accordingly, healthcare providers can optimize treatment outcomes and enhance patient well-being.